164 related articles for article (PubMed ID: 31023612)
1. Identification of genetic alterations in extramammary Paget disease using whole exome analysis.
Kiniwa Y; Yasuda J; Saito S; Saito R; Motoike IN; Danjoh I; Kinoshita K; Fuse N; Yamamoto M; Okuyama R
J Dermatol Sci; 2019 Apr; 94(1):229-235. PubMed ID: 31023612
[TBL] [Abstract][Full Text] [Related]
2. Unbiased Detection of Driver Mutations in Extramammary Paget Disease.
Ishida Y; Kakiuchi N; Yoshida K; Inoue Y; Irie H; Kataoka TR; Hirata M; Funakoshi T; Matsushita S; Hata H; Uchi H; Yamamoto Y; Fujisawa Y; Fujimura T; Saiki R; Takeuchi K; Shiraishi Y; Chiba K; Tanaka H; Otsuka A; Miyano S; Kabashima K; Ogawa S
Clin Cancer Res; 2021 Mar; 27(6):1756-1765. PubMed ID: 33323405
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the biomarkers for targeted therapies in primary extra-mammary and mammary Paget's disease.
Gatalica Z; Vranic S; Krušlin B; Poorman K; Stafford P; Kacerovska D; Senarathne W; Florento E; Contreras E; Leary A; Choi A; In GK
Cancer Med; 2020 Feb; 9(4):1441-1450. PubMed ID: 31899853
[TBL] [Abstract][Full Text] [Related]
4. Whole-Exome Sequencing Reveals Frequent Mutations in Chromatin Remodeling Genes in Mammary and Extramammary Paget's Diseases.
Zhang G; Zhou S; Zhong W; Hong L; Wang Y; Lu S; Pan J; Huang Y; Su M; Crawford R; Zhou Y; Mai R
J Invest Dermatol; 2019 Apr; 139(4):789-795. PubMed ID: 30905357
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic mutations in extramammary Paget's disease and their clinical relevance.
Kang Z; Xu F; Zhang QA; Wu Z; Zhang X; Xu J; Luo Y; Guan M
Int J Cancer; 2013 Feb; 132(4):824-31. PubMed ID: 22821211
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget's disease.
Chen S; Moroi Y; Urabe K; Takeuchi S; Kido M; Hayashida S; Uchi H; Uenotsuchi T; Tu Y; Furue M
Clin Exp Dermatol; 2008 Aug; 33(5):634-40. PubMed ID: 18627398
[TBL] [Abstract][Full Text] [Related]
8. Genetic Analysis of Mismatch Repair Genes Alterations in Extramammary Paget Disease.
Kang Z; Xu F; Zhu Y; Fu P; Zhang QA; Hu T; Li X; Zhang Q; Wu Z; Zhang X; Wang H; Xu J; Fang Z; Guan M
Am J Surg Pathol; 2016 Nov; 40(11):1517-1525. PubMed ID: 27487738
[TBL] [Abstract][Full Text] [Related]
9. Whole genome methylation sequencing reveals epigenetic landscape and abnormal expression of FABP5 in extramammary Paget's disease.
Kang Z; Jiang L; Chen D; Yan G; Zhang G; Lai Y; Zeng Q; Wang X
Skin Res Technol; 2023 Oct; 29(10):e13497. PubMed ID: 37881057
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of circulating tumour DNA in metastatic extramammary Paget's disease.
Sawamura S; Mijiddorj Myangat T; Kajihara I; Tanaka K; Ide M; Sakamoto R; Otsuka-Maeda S; Kanemaru H; Nishimura Y; Kanazawa-Yamada S; Kashiwada-Nakamura K; Honda N; Makino K; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Ihn H
Exp Dermatol; 2022 Mar; 31(3):341-348. PubMed ID: 34676917
[TBL] [Abstract][Full Text] [Related]
11. Serum cell-free DNA levels are a useful marker for extramammary Paget disease.
Mijiddorj T; Kajihara I; Tasaki Y; Otsuka-Maeda S; Sakamoto R; Sawamura S; Kanazawa-Yamada S; Egashira S; Inoue K; Makino K; Miyashita A; Aoi J; Igata T; Makino T; Masuguchi S; Fukushima S; Jinnin M; Morinaga J; Ikeda T; Ihn H
Br J Dermatol; 2019 Sep; 181(3):505-511. PubMed ID: 30706452
[TBL] [Abstract][Full Text] [Related]
12. Concordance of the HER2 protein and gene status between primary and corresponding lymph node metastatic sites of extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Takahashi A; Tsutsumida A; Fujisawa Y; Fujimoto M; Yamazaki N
Clin Exp Metastasis; 2016 Oct; 33(7):687-97. PubMed ID: 27289366
[TBL] [Abstract][Full Text] [Related]
13. Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget's disease.
Kang Z; Xu F; Zhang QA; Lin J; Wu Z; Zhang X; Luo Y; Xu J; Guan M
Mod Pathol; 2012 Aug; 25(8):1160-8. PubMed ID: 22522847
[TBL] [Abstract][Full Text] [Related]
14. Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report.
Lim BY; Guo Z; Lim JQ; Ko TK; Lee ECY; Kannan B; Lee JY; Lim AH; Li Z; Ng CC; Busmanis I; Chan JY
Orphanet J Rare Dis; 2024 Jun; 19(1):223. PubMed ID: 38831459
[TBL] [Abstract][Full Text] [Related]
15. PIG7/LITAF gene mutation and overexpression of its gene product in extramammary Paget's disease.
Matsumura Y; Matsumura Y; Nishigori C; Horio T; Miyachi Y
Int J Cancer; 2004 Aug; 111(2):218-23. PubMed ID: 15197774
[TBL] [Abstract][Full Text] [Related]
16. Intertumor and intratumor heterogeneity of PIK3CA mutations in extramammary Paget's disease.
Kusaba Y; Kajihara I; Myangat TM; Tanaka K; Sakamoto R; Maeda-Otsuka S; Yamada-Kanazawa S; Sawamura S; Kanemaru H; Nishimura Y; Nakamura-Kashiwada K; Makino K; Miyashita A; Aoi J; Masuguchi S; Fukushima S
J Dermatol; 2022 May; 49(5):508-514. PubMed ID: 35253277
[TBL] [Abstract][Full Text] [Related]
17. Extramammary Paget's disease patient-derived xenografts harboring ERBB2 S310F mutation show sensitivity to HER2-targeted therapies.
Maeda T; Kitamura S; Nishihara H; Yanagi T
Oncogene; 2020 Sep; 39(36):5867-5875. PubMed ID: 32724160
[TBL] [Abstract][Full Text] [Related]
18. Serum cytokeratin 19 fragment 21-1 and carcinoembryonic antigen combination assay as a biomarker of tumour progression and treatment response in extramammary Paget disease.
Nakamura Y; Tanese K; Hirai I; Amagai M; Kawakami Y; Funakoshi T
Br J Dermatol; 2019 Sep; 181(3):535-543. PubMed ID: 30791097
[TBL] [Abstract][Full Text] [Related]
19. MiR-155, a potential serum marker of extramammary Paget's disease.
Guo H; Qi RQ; Sheng J; Liu C; Ma H; Wang HX; Li JH; Gao XH; Wan YS; Chen HD
BMC Cancer; 2018 Nov; 18(1):1078. PubMed ID: 30458743
[TBL] [Abstract][Full Text] [Related]
20. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
